Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INFU 
InfuSystems Holdings Inc (INFU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: INFU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14.2
1 Year Target Price $14.2
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.88% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 183.22M USD | Price to earnings Ratio 34.5 | 1Y Target Price 14.2 |
Price to earnings Ratio 34.5 | 1Y Target Price 14.2 | ||
Volume (30-day avg) 4 | Beta 1.7 | 52 Weeks Range 4.61 - 11.04 | Updated Date 12/2/2025 |
52 Weeks Range 4.61 - 11.04 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When - | Estimate 0.0775 | Actual 0.1479 |
Profitability
Profit Margin 3.92% | Operating Margin (TTM) 10.44% |
Management Effectiveness
Return on Assets (TTM) 7.24% | Return on Equity (TTM) 9.96% |
Valuation
Trailing PE 34.5 | Forward PE 26.45 | Enterprise Value 212253416 | Price to Sales(TTM) 1.3 |
Enterprise Value 212253416 | Price to Sales(TTM) 1.3 | ||
Enterprise Value to Revenue 1.5 | Enterprise Value to EBITDA 8.79 | Shares Outstanding 20336183 | Shares Floating 19235589 |
Shares Outstanding 20336183 | Shares Floating 19235589 | ||
Percent Insiders 6.89 | Percent Institutions 76.14 |
Upturn AI SWOT
InfuSystems Holdings Inc
Company Overview
History and Background
InfuSystems Holdings Inc. was founded in 1992. It has evolved from a regional provider of infusion services to a national leader specializing in infusion therapy for chronic and acute conditions.
Core Business Areas
- Infusion Services: Provides infusion therapy services to patients in the comfort of their homes or at its Ambulatory Infusion Suites (AIS). This segment focuses on managing complex therapies for various conditions.
- Medical Equipment Services: Provides infusion pumps and related supplies for home infusion therapy. Includes rental, sales, and maintenance of equipment.
Leadership and Structure
Richard DiIorio is the Chief Executive Officer. The company has a board of directors and operates with functional departments for finance, operations, and sales.
Top Products and Market Share
Key Offerings
- Home Infusion Therapy: Provides comprehensive infusion therapy services at home, reducing hospital readmissions and improving patient outcomes. Market share is difficult to pinpoint precisely but InfuSystems is one of the larger players in a fragmented market. Competitors include Option Care Health, CVS Health (Coram), and Walgreens (AllianceRx Walgreens Prime).
- Ambulatory Infusion Suites (AIS): Offers a convenient and cost-effective alternative to hospital-based infusion services. Revenue from AIS is a growing segment. Competition includes other regional and national AIS providers and hospital outpatient clinics.
Market Dynamics
Industry Overview
The home infusion therapy market is growing due to factors such as an aging population, increasing prevalence of chronic diseases, and the shift towards value-based healthcare. Growth also stems from the desire for in-home care.
Positioning
InfuSystems is positioned as a national provider of home infusion services and related medical equipment. Its competitive advantages include its established network, expertise in complex therapies, and focus on patient care.
Total Addressable Market (TAM)
The total addressable market (TAM) for home infusion therapy is estimated to be in the tens of billions of dollars annually. InfuSystems holds a small but significant percentage of the TAM and is aiming to expand through organic growth and acquisitions.
Upturn SWOT Analysis
Strengths
- National Provider Network
- Expertise in Complex Infusion Therapies
- Strong Relationships with Payors
- Growing AIS network
- Focus on Patient Outcomes
Weaknesses
- High Dependence on Reimbursement Rates
- Exposure to Regulatory Changes
- Competition from Larger Healthcare Providers
- High debt load
Opportunities
- Expanding into New Geographic Markets
- Acquiring Smaller Infusion Providers
- Developing New Infusion Therapies
- Growth in Biologic Infusions
Threats
- Changes in Healthcare Regulations
- Increased Competition
- Pressure on Reimbursement Rates
- Cybersecurity risks
Competitors and Market Share
Key Competitors
- OPCH
- CVS
- WBA
Competitive Landscape
InfuSystems faces intense competition from larger, more diversified healthcare providers. Its strengths lie in its specialized expertise and focus on patient care. However, it needs to manage reimbursement pressures and regulatory changes effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been steady, driven by organic growth and acquisitions. However, past performance is not indicative of future results given accounting issues.
Future Projections: Future growth depends on the resolution of current challenges. Analyst estimates vary based on expectations for the company's ability to navigate regulatory and competitive pressures.
Recent Initiatives: Recent initiatives include expanding its AIS network and strengthening relationships with payers.
Summary
InfuSystems Holdings Inc. is a national provider of home infusion services facing both opportunities and challenges. While it has a strong network and expertise, reimbursement pressures and regulatory changes present significant risks. The company needs to navigate these challenges effectively to capitalize on the growing demand for home infusion therapy. The company has recently had accounting issues and has not reported financials for many periods.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, analyst estimates
- Yahoo Finance
- MarketWatch
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Financial data may be inaccurate due to restatements.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InfuSystems Holdings Inc
Exchange NYSE MKT | Headquaters Rochester Hills, MI, United States | ||
IPO Launch date 2007-12-27 | President, CEO & Director Ms. Carrie A. Lachance B.S.N., M.B.A., R.N. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 502 | Website https://www.infusystem.com |
Full time employees 502 | Website https://www.infusystem.com | ||
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates in two segments, Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.